|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:associated_with
|
opioid epidemic
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Oxy_Contin
|
|
gptkbp:clinical_trial
|
safety studies
pain relief studies
long-term efficacy studies
abuse potential studies
comparative studies with other opioids
|
|
gptkbp:contraindication
|
severe asthma
intestinal obstruction
|
|
gptkbp:developed_by
|
gptkb:Purdue_Pharma
|
|
gptkbp:dosage_form
|
gptkb:II
|
|
gptkbp:education
|
disposal methods
proper storage
risk of addiction
|
|
gptkbp:environmental_impact
|
high
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oxy Contin
|
|
gptkbp:ingredients
|
oxycodone
C18 H21 N O4
|
|
gptkbp:interacts_with
|
CY P2 D6 inhibitors
CY P3 A4 inhibitors
|
|
gptkbp:introduced
|
gptkb:1996
|
|
gptkbp:is_used_for
|
pain management
|
|
gptkbp:legal_issue
|
lawsuits
|
|
gptkbp:lifespan
|
3 to 6 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
Oxycodone hydrochloride
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
strict
|
|
gptkbp:products
|
gptkb:Fentanyl
gptkb:Percocet
Morphine
Hydrocodone
Vicodin
|
|
gptkbp:public_perception
|
controversial
widely criticized
addiction crisis contributor
misuse and abuse concerns
|
|
gptkbp:reform
|
gptkb:2010
abuse deterrence
|
|
gptkbp:side_effect
|
nausea
drowsiness
constipation
|
|
gptkbp:symptoms
|
anxiety
muscle pain
insomnia
|
|
gptkbp:weight
|
315.4 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Arthur_M._Sackler
gptkb:Purdue_Pharma
|
|
gptkbp:bfsLayer
|
5
|